Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Evolution of Pulmonary Ultrasound in Patients Hospitalized for Covid (Coronavirus Disease) 19

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04341766
Recruitment Status : Completed
First Posted : April 10, 2020
Last Update Posted : July 17, 2020
Sponsor:
Information provided by (Responsible Party):
Centre Hospitalier Intercommunal Creteil

Brief Summary:

Clinical thoracic ultrasound plays an important role in the exploration, diagnosis and follow-up of thoracic pathologies.

The COVID (Coronavirus Disease) epidemic is leading to a large influx of patients in the emergency department with respiratory disorders. The rapid diagnosis of respiratory disorders in infected patients is important for further management.

Chest ultrasound has already demonstrated its value in the diagnosis of pneumonia in the emergency department with superiority over chest X-ray.

However, there is little data on the thoracic ultrasound semiology of viral pneumonia in general and of COVID in particular.


Condition or disease Intervention/treatment
Pneumonia, Viral COVID-19 Other: No special intervention

Detailed Description:

Chest ultrasound has already shown its value in the diagnosis of pneumonia in the emergency department with superiority over chest X-ray.

However, there is little data on the thoracic ultrasound semiology of viral pneumonia in general and of COVID in particular.

Peng reported data from 20 patients and compared them to chest CT. The abnormalities are a thickening of the pleuropneumonia line, an interstitial syndrome with B lines, corresponding to frosted glass opacities, confluent B lines (snowstorm appearance) corresponding to interstitial infiltrate, sub-pleural alveolar opacities corresponding to sub-pleural condensations, more frank alveolar images corresponding to alveolar opacities. A multifocal aspect was associated with involvement of more than 2 lobes. However, the frequency of these abnormalities as well as the sensitivity of the echo are not detailed in this article.

Another Italian article describes a clinical case of COVID-19 pneumonia with sub-pleural involvement and irregularity of the pleuro-pulmonary line.

Clinical thoracic ultrasound has a major potential interest during the COVID epidemic: available at the patient's bedside, avoiding the need to move around, feasible for the physician during his visit, easy to clean especially if ultraportable devices are used, fast and not exposing the staff any more than the usual clinical examination.

In order to determine whether this technique is useful in the management of infected patients or patients suspected of COVID-19 infection with respiratory signs, we propose a descriptive prospective study evaluating the ultrasound semiology of COVID-19 pneumonia and the interest of ultrasound in the evolutionary follow-up of these patients.

Layout table for study information
Study Type : Observational [Patient Registry]
Actual Enrollment : 106 participants
Observational Model: Cohort
Time Perspective: Prospective
Target Follow-Up Duration: 6 Weeks
Official Title: Prospective Descriptive Study on the Evolution of Pulmonary Ultrasound in Patients Hospitalized for Covid19
Actual Study Start Date : March 31, 2020
Actual Primary Completion Date : May 27, 2020
Actual Study Completion Date : June 30, 2020

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Ultrasound

Group/Cohort Intervention/treatment
Patient hospitalised with COVID-19 infection
Patients admitted to hospital with proven COVID-19 infection with respiratory signs warranting a chest CT scan
Other: No special intervention
No special intervention : Ultrasound data will be collected




Primary Outcome Measures :
  1. Characteristics of pulmonary ultrasound for Covid-19 patients [ Time Frame: Day one ]
    description of ultrasound abnormalities for Covid-19 patients


Secondary Outcome Measures :
  1. Characteristics of pulmonary ultrasound for Covid-19 patients [ Time Frame: Day 3 ]
    description of ultrasound abnormalities for Covid-19 patients

  2. Characteristics of pulmonary ultrasound for Covid-19 patients [ Time Frame: Day 14 ]
    description of ultrasound abnormalities for Covid-19 patients

  3. Charateristics of pulmonary CT-scan for Covid-19 patients [ Time Frame: Day 1 ]
    description of CT-scan abnormalities for Covid-19 patients

  4. Charateristics of pulmonary CT-scan for Covid-19 patients [ Time Frame: Day 3 ]
    description of CT-scan abnormalities for Covid-19 patients

  5. Charateristics of pulmonary CT-scan for Covid-19 patients [ Time Frame: Day 14 ]
    description of CT-scan abnormalities for Covid-19 patients



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 105 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patient admitted to hospital with proven COVID-19 infection with respiratory signs and who need an hospitalization
Criteria

Inclusion Criteria:

  • Patients admitted to hospital with proven COVID-19 infection with respiratory signs warranting a chest CT scan

Exclusion Criteria:

  • Patient not agreeing to have his or her data collected for the study
  • Unconscious patient

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04341766


Locations
Show Show 17 study locations
Sponsors and Collaborators
Centre Hospitalier Intercommunal Creteil
Layout table for additonal information
Responsible Party: Centre Hospitalier Intercommunal Creteil
ClinicalTrials.gov Identifier: NCT04341766    
Other Study ID Numbers: COVID-ECHO
First Posted: April 10, 2020    Key Record Dates
Last Update Posted: July 17, 2020
Last Verified: July 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Pneumonia, Viral
Pneumonia
Lung Diseases
Respiratory Tract Diseases
Respiratory Tract Infections
Virus Diseases